SCYX
Scynexis, Inc.
A biotechnology company in Jersey City, New Jersey, that develops medicines for hard-to-treat infections and rare diseases. Its best-known product is Brexafemme, an oral pill for vaginal yeast infections that was the first new class of antifungal drug approved by the FDA in more than twenty years. The company began in 1999 as a chemistry-and-automation services firm called ScyRex, later renamed SCYNEXIS, and today also works on treatments for polycystic kidney disease.
CUSIP: 811292200HealthcareUS1 holder
Total Value
$922.0K
Total Shares
174.0K
Net Share Change
+174.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
